Failed ABO incompatible high titers kidney transplant using bortezomib. Case report  by De Sousa-Amorim, Erika et al.
CF
b
F
c
D
A
a
s
s
d
i
t
c
B
t
a
s
b
n
p
e
t
s
d
I
c
t
l
A
A
s
e
H
m
i
o
an e f r o l o g i a 2 0 1 6;3 6(6):701–704
www.rev is tanef ro logia .com
Revista de la Sociedad Española de Nefrología
ase report
ailed  ABO  incompatible  high titers  kidney  transplant  using
ortezomib. Case  reportracaso  en  el  uso  de  bortezomib  en  el  trasplante  ABO  incompatible
oon  titulos  altos.  Reporte  de  un  cas
ear Editor:
BO-incompatible (ABO-i) kidney transplantation (KT) has
chieved remarkable clinical success in the last decades,
urvival rates of ABO-compatible and ABO-i KT have been
hown to be similar.1,2 However, there is a higher inci-
ence of humoral rejection and early graft loss, especially
n patients with high pretreatment anti-ABO antibody (Ab)
iters.3,4
Current strategies for desensitization are variable among
enters, consisting of extracorporeal removal of anti-ABO Ab,
-cell depletion and intensiﬁed immunosuppression. The ini-
ial goal is to decrease anti-ABO Ab titers before surgery
nd most centers have adhered to the guideline that titers
hould be ≤1:16 before transplantation, a limit which has been
ased on empirical evidence. The proportion of cases that do
ot respond to desensitization and therefore cannot be trans-
lanted under current strategies is unknown, and there is no
stablish limit titer (pre-treatment) above which desensitiza-
ion may not be successful. A previous report from Gloor et al.
howed graft loss to occur when the baseline titer was 1:512
espite intensive therapy.5
In our center, since 2006 we have performed 67 ABOi KT.
n our protocol high anti-ABO Ab titers (deﬁned as ≥1:512) are
onsider to preclude transplantation. For those cases, we offer
he paired exchange program and the cadaveric donor waiting
ist. However, there are some reports of successful high titer
BOi KT in the literature 6–9 and it is plausible that high anti
BO Ab titers may be decreased using a more  potent immuno-
uppressive approach.
Our standard protocol includes rituximab, plasma
xchanges (PE) and intravenous immunoglobulins (IVIG).
owever, our current regimen has no signiﬁcant effect on
ature plasma cells, which are the major source of antibod-
es. Bortezomib, a proteasome inhibitor, used in the treatment
f multiple myeloma (MM),  causes apoptosis of plasma cells
nd have been successfully used for desensitization in HLAincompatible KT,10,11 thus bortezomib could be useful as well
for desensitization in ABO-i KT.
Here in, we present a case of high titer ABO incompatible KT
attempt using bortezomib in addition to our standard protocol.
We  report the case a 32 years old female with chronic kid-
ney disease secondary to ANCA vasculitis started hemodialy-
sis in February 2012. A spousal living donor was studied; ABO
incompatible A1 to O with anti-A Ab titers of IgM 128: IgG 512.
In 2012, due to high titers transplantation was not advised.
After three years on the cadaveric donor waiting list and in the
paired exchange Spanish program, with no success in achiev-
ing a suitable donor, an attempt of performing an ABO-i KT
was initiated.
We  decided to use bortezomib in addition to the standard
protocol with the goal to decrease the anti-A antibody to a titer
of ≤8.
Bortezomib dose was adjusted to 1 mg/m2 in concordance
with our previous experience of moderate to severe adverse
events in KT patients treated with bortezomib for
acute humoral rejection (personal communication).
Five weeks prior to surgery, the patient received two weekly
doses of rituximab 400 mg  each, one cycle of bortezomib, con-
sisting of four doses of 1 mg/m2 administered intravenous
post-PE in days 1, 4, 8 and 11, twelve sessions of PE and low
dose IVIG (200 mg/kg every two PE). Maintenance immuno-
suppression was initiated with tacrolimus, mycophenolate
mofetil and prednisone (Fig. 1).
After ﬁve weeks of treatment, IgG titer post-PE was 8, but
we observed a rebound of IgG titer to 32 in the morning
before surgery, thus transplantation was postponed. A second
attempt of transplantation was made a week later, after six
sessions of daily PE and IVIG but titers remained unchanged,
with IgG titer post-PE of 8 and pre-surgery of 32.An additional cycle of bortezomib plus 8 PE and IVIG was
given. Finally, nine weeks after initiation of treatment, anti-
A IgG titers post-PE were 16 and there was a rebound to 64,
which precluded transplantation (Fig. 2).
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Fig. 1 – Desensitization protocol, including the three phases of consecutive treatment. RTX, rituximab; BTZ, bortezomib; PE,
plasma exchange; IVIG intravenous immunoglobulins.
The treatment was well tolerated, except for a severe aller-
gic reaction to fresh frozen plasma presented in the last PE
session that required treatment with dexchlorpheniramine,
ranitidine, corticosteroids and adrenaline. Six months after
failed desensitization, the patient remains well in hemodial-
ysis, without any infectious complication.
In this letter, we report our ﬁrst experience in ABO-i KT with
anti-ABO IgG titers ≥512, which was unsuccessful despite a
very intensive immunosuppressive treatment including borte-
zomib, rituximab, plasma exchanges and IVIG.
Baseline high anti-ABO Ab have been shown to be the
strongest predictor of ABO-i KT outcomes, and are associ-
ated with higher incidence of humoral rejection and early
graft loss.3,4 Previous experience suggest that although pre-
transplant treatment can reduce anti-ABO Ab to low levels
at the time of transplantation, many  patients rebound to
high levels in the early post-transplant period, resulting in
antibody-mediated damage to the allograft.4 A previous report
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Fig. 2 – Course of IgG anti-A titers during treatment and pre and
titers achieved at the end of each treatment phase.showed graft loss to occur when the baseline titer was 1:512
despite intensive post transplantation PE/IVIG therapy and
patients with elevated baseline antibody titer (≥1:256) appear
to be at high risk for humoral rejection.5 However, the limit for
patients with high anti-ABO Ab titers that can safely undergo
transplantation is unclear.
Some centers have reported successful ABO-i KT in
patients with anti-ABO Ab titers up to 2048, using a regimen
including rituximab, PE on doubled ﬁltration plasmaphere-
sis, with or without splenectomy, reporting rates of failed
desensitization ranging from 0 to 16%, although the number
of cases is limited.6–8 A major problem is the lack of stan-
dardization in anti ABO Ab measurement. There are various
methods to measure titers, the most common is the saline
tube technique, although this technique yields signiﬁcant
intercenter variation.12 New techniques, such as gel card
technique and ﬂow cytometry, have shown better improved
reproducibility,12,13 but still anti-ABO Ab measurements
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mong centers may not be comparable. In our institution,
e measure anti-ABO antibodies trough haemagglutination
ethod using donor erythrocytes in gel cards and the isoag-
lutin titer is deﬁned as the last dilution that gives in a gel
ard an agglutination intensity of +2 or bigger.
There is little data on the use of proteasome inhibitors for
BO-i KT. Benken et al., reported seven cases of ABO-i KT using
ortezomib, including one patient with high anti-ABO titer
1:1024), but details on treatment administered (dosing, num-
er of cycles and outcomes) are lacking.14 Also, Wong et al.,
eported one case of ABO-i and positive crossmatch KT per-
ormed using bortezomib, but in this particular case, anti ABO
iters decrease after PE and IVIG, and bortezomib was given
ater due to positive crossmatch.15
There is no data regarding the appropriate dosing and
he number of cycles of bortezomib to be used for ABO-i KT,
ore over current treatment schedules used in nephrology
or other indications (treatment of acute mediated rejection
r desensitization) were copied from the experience in MM.
n important concern for treating patients with bortezomib
ay be the presence of renal failure. Formal studies are under
ay to deﬁne the pharmacokinetics and safety of bortezomib
ith varying renal impairment, but until now experience in
M patients with renal failure, showed that dose modiﬁcation
nd treatment discontinuation rates were higher and the inci-
ence of serious adverse effects (≥ grade 3) was increased.16
urrent recommendations for MM patients with renal impair-
ent advised no dose adjustment but careful assessment, and
n cases of signiﬁcant toxicities, dose reduction is advised.17
So far, evidence to support a potential beneﬁcial effect
f bortezomib in ABO incompatible kidney transplantation is
acking. In our experience, adding bortezomib to the standard
esensitization protocol was not useful in a patient with high
nti-ABO antibodies titer, but more  research in this ﬁeld will
e needed.
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